<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03724097</url>
  </required_header>
  <id_info>
    <org_study_id>OB0052018</org_study_id>
    <nct_id>NCT03724097</nct_id>
  </id_info>
  <brief_title>Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy</brief_title>
  <official_title>Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OmicsWay Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oncobox Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vitamed LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>N.N. Blokhin National Medical Research Center of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaluga Regional Clinical Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Multidisciplinary medical holding SM-Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncological Clinical Dispensary No. 1 of the Moscow City Health Department</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OmicsWay Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective trial for a computation-based efficacy prediction method for anticancer
      target therapies. The original computational algorithm utilizes individual transcriptome data
      of a cancer sample and assesses changes at the level of gene expression and intracellular
      signaling pathways. By applying the database of known molecular targets of anticancer target
      drugs it allows to rank potential efficacies of target drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Original computational algorithm Oncobox was developed to determine molecular features of
      individual tumors. It represents the solution for a personalized selection of target
      anticancer therapies. The method is based on the analysis of gene expression profile of a
      cancer sample in comparison with the corresponding normal tissue biosamples in order to
      select the most effective molecular targets for their inhibition and, accordingly, to
      identify more effective target drugs for cancer treatment. Histological material obtained
      from cancer patients during surgery or core-needle biopsy as part of standard treatment will
      be used for the analysis. Total RNA extracted from the tumor material will be subjected to
      next-generation sequencing (NGS). By comparing transcriptome profile of the tumor sample with
      the profiles of the corresponding normal tissue samples the rate of molecular pathways
      activation/deactivation will be calculated, as well as the case-to-normal ratios for the
      individual gene products - molecular targets of drugs. Based on these data, each target drug
      will be assigned with a score reflecting its potential efficacy for each individual tumor
      treatment. A drug with the score value above 0.1 will be considered potentially effective, a
      drug with the score value equal to or below 0.1 - as potentially ineffective. Following
      Oncobox test, 130 target anticancer drugs will be rated according to their predicted
      effectiveness (see the list of eligible target drugs below). This information will be fully
      available to a patient and his/her doctor. The doctor will prescribe treatment according to
      his/her consideration, e.g. based on the standards of care and the patient's life
      indications. After the appointment of therapy, the patients will be divided naturally into
      the following three observation groups. The first group will be formed from patients
      receiving target drugs with the score value above 0,1 as monotherapy or in combination. The
      second group - patients receiving only non-target drugs or target drugs with the score value
      equal to or below 0,1 as monotherapy or in combination. Third group will be formed by
      patients receiving palliative care. Within this study, these three groups will be compared by
      response to the therapy according to the results of instrumental studies, by time to
      progression and by time to progression compared to the previous line of therapy (if any).
      Additionally, overall survival will be measured in all three groups.

      Eligible target drugs:

        1. Abemaciclib (LY2835219)

        2. Afatinib

        3. Aflibercept

        4. Alectinib

        5. Alemtuzumab

        6. Alitretinoin

        7. Anastrozole

        8. Apalutamide, ARN-509

        9. Arsenic trioxide

       10. Atezolizumab

       11. Avelumab

       12. Axitinib

       13. Belinostat

       14. Bevacizumab

       15. Bexarotene

       16. Bicalutamide

       17. Binimetinib (MEK162)

       18. Blinatumomab

       19. Bortezomib

       20. Bosutinib

       21. Brentuximab vedotin

       22. Brigatinib

       23. Cabazitaxel

       24. Cabozantinib

       25. Carfilzomib

       26. Ceritinib (Zykadia, LDK378)

       27. Cetuximab

       28. Cobimetinib

       29. Crizotinib

       30. CYT387 (Momelotinib)

       31. Dabrafenib

       32. Daratumumab

       33. Dasatinib

       34. Degarelix

       35. Denileukin diftitox (Ontac)

       36. Denosumab

       37. Docetaxel

       38. Dovitinib

       39. Durvalumab

       40. Elotuzumab

       41. Encorafenib

       42. Enzalutamide

       43. Erlotinib

       44. Estramustine

       45. Everolimus

       46. Exemestane

       47. Flavopiridol (Alvociclib)

       48. Foretinib

       49. Fulvestrant

       50. Ganetespib (STA-9090)

       51. Gefitinib

       52. Goserelin

       53. Homoharringtonine (Omacetaxine mepesuccinate)

       54. Ibritumomab tiuxetan

       55. Ibrutinib

       56. Idelalisib

       57. Imatinib

       58. Inotuzumab ozogamicin

       59. Ipilimumab

       60. Ixabepilone

       61. Ixazomib (MLN9708)

       62. Lapatinib

       63. Lenalidomide

       64. Lenvatinib

       65. Letrozole

       66. Leuprolide

       67. Lomustine

       68. Masitinib

       69. Medroxyprogesterone acetate (MPA)

       70. Megestrol

       71. Methyltestosterone

       72. Midostaurin

       73. Mogamulizumab

       74. Moxetumomab pasudotox

       75. Necitumumab

       76. Nilotinib

       77. Nilutamide

       78. Nimotuzumab

       79. Nintedanib (BIBF 1120)

       80. Niraparib

       81. Nivolumab (BMS-936558)

       82. Obinutuzumab

       83. Ofatumumab

       84. Olaparib

       85. Olaratumab

       86. Osimertinib

       87. Paclitaxel

       88. Palbociclib

       89. Panitumumab

       90. Panobinostat

       91. Pazopanib

       92. Pembrolizumab

       93. Perifosine

       94. Pertuzumab

       95. Pomalidomide

       96. Ponatinib

       97. Ramucirumab (Cyramza)

       98. Regorafenib

       99. Ribociclib

      100. Rigosertib

      101. Rituximab

      102. Romidepsin

      103. Rucaparib

      104. Ruxolitinib

      105. Selumetinib

      106. Siltuximab

      107. Sonidegib (LDE225)

      108. Sorafenib

      109. Sunitinib

      110. Tamoxifen

      111. Tecemotide (Emepepimut-S, L-BLP25)

      112. Temozolomide

      113. Temsirolimus

      114. Thalidomide

      115. Tivantinib

      116. Tivozanib

      117. Toremifene

      118. Trametinib (Mekinst)

      119. Trastuzumab

      120. Trebananib

      121. Vandetanib

      122. Veliparib

      123. Vemurafenib

      124. Venetoclax

      125. Vinblastine

      126. Vincristine

      127. Vindesine

      128. Vinorelbine

      129. Vismodegib

      130. Vorinostat
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>2 years</time_frame>
    <description>Tumor response according to the results of instrumental studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>2 years</time_frame>
    <description>Time to progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression compared to the previous therapy lane</measure>
    <time_frame>2 years</time_frame>
    <description>Time to progression compared to the previous therapy lane</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients receiving target drugs with the score value above 0,1 as monotherapy or in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Patients receiving only non-target drugs or target drugs with the score value equal to or below 0,1 as monotherapy or in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Patients receiving palliative care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RNA sequencing</intervention_name>
    <description>Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>RNA-seq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transcriptome analysis</intervention_name>
    <description>Analysis of RNA-seq data using the Oncobox algorithm.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>target drug with the score above 0,1</intervention_name>
    <description>target drug with the score above 0,1</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>target drug with the score equal or below 0,1</intervention_name>
    <description>target drug with the score equal or below 0,1</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-target drug</intervention_name>
    <description>non-target drug</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palliative care</intervention_name>
    <description>palliative care</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin-fixed, paraffin-embedded pathological cancer samples obtained during surgery or core
      needle biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Oncological patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, diagnosed with cancer;

          -  Age 18 - 80;

          -  Patients who previously received anticancer treatment within the standard care,
             patients for whom standard therapy was not indicated or patients refused to receive
             standard therapy. Patients could receive an unlimited number of treatment lines before
             this study;

          -  Available formalin fixed, paraffin-embedded (FFPE) samples of cancer tissue. The
             material should be confirmed by a certified pathologist, the sample taken for the
             analysis should contain at least 70% of tumor cells;

          -  Anticipated survival of at least 3 months since the patient's inclusion in the current
             investigation;

          -  Patients who have signed an informed consent.

        Exclusion Criteria:

          -  Anticipated survival of less than 3 months since the patient's inclusion in the
             current investigation;

          -  Lack of tumor biopsy material, inability to obtain a new tumor biopsy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anton A Buzdin, Ph.D., D.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>OmicsWay Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anton A Buzdin, Ph.D., D.Sc</last_name>
    <phone>+18883822725</phone>
    <email>buzdin@oncobox.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aleksander A Glusker, PhD, MD</last_name>
    <phone>+79857841446</phone>
    <email>glusker@oncobox.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OmicsWay Corp.</name>
      <address>
        <city>Walnut</city>
        <state>California</state>
        <zip>91789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton A Buzdin, Ph.D., D.Sc</last_name>
      <phone>888-382-2725</phone>
      <email>buzdin@oncobox.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaluga Regional Clinical Oncology Center</name>
      <address>
        <city>Kaluga</city>
        <zip>248007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry S Lantsov, MD</last_name>
      <phone>+79109160700</phone>
      <email>lantsov@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncological Clinical Dispensary No. 1 of the Moscow City Health Department</name>
      <address>
        <city>Moscow</city>
        <zip>105005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry G Sokov, MD</last_name>
      <phone>+79152070284</phone>
      <email>sokov77@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multidisciplinary medical holding &quot;SM-Clinic&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>109316</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksander P Seryakov, MD</last_name>
      <phone>+79163388112</phone>
      <email>seryakov.ap@smpost.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin National Medical Research Center of Oncology</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David R Naskhletashvili, MD</last_name>
      <phone>+79255176653</phone>
      <email>nas-david@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Oncobox&quot; Ltd.</name>
      <address>
        <city>Moscow</city>
        <zip>121205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksander A Glusker, PhD, MD</last_name>
      <phone>+79857841446</phone>
      <email>glusker@oncobox.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vitamed LLC</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena V Poddubskaya, MD</last_name>
      <phone>+79857695758</phone>
      <email>podd-elena@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 26, 2018</study_first_submitted>
  <study_first_submitted_qc>October 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>October 26, 2018</last_update_submitted>
  <last_update_submitted_qc>October 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarkers</keyword>
  <keyword>target therapy</keyword>
  <keyword>NGS</keyword>
  <keyword>RNAseq</keyword>
  <keyword>mRNA</keyword>
  <keyword>transcriptome analysis</keyword>
  <keyword>signaling pathway</keyword>
  <keyword>intracellular molecular pathway</keyword>
  <keyword>Oncobox</keyword>
  <keyword>Next generation sequencing</keyword>
  <keyword>RNA sequencing</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study Protocol, Statistical Analysis Plan (SAP), NGS data, Clinical Study Report (CSR)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months after trial completion, no end date</ipd_time_frame>
    <ipd_access_criteria>Anyone</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

